RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer (Video Program) - Video 15Management of nausea and vomiting in patients receiving olaparib
1:30 minutes.
TRANSCRIPTION:
DR MATULONIS: So we mostly learned that the side effects are present, not surprising. And I think also that what can end up happening is that there’s a buildup of tolerance to these side effects. So if a patient starts to develop some nausea or vomiting, or anorexia or dyspepsia, if she can tolerate the medications, more often than not those side effects will get better. Exactly why that occurs, not sure, but those side effects tend to get better. In a less ideal world, you’d give that patient a break. But I think that — and I think this is another important point that I want to make. For PARP inhibitors, these drugs are meant to be given continuously. So I think I would really — unless the patient is having a lot of distress, I think taking away the PARP inhibitor, giving her a break, may not be the best thing to do, but to continue that continuous therapy. Obviously, if she’s miserable, you’ve got to give her a break. Because that’s what we learned from that, is that, yes, there are toxicities. They tend to get better with time. DR LOVE: I’m not sure what it means, but I see that you also looked at the time that the patient got the drug, morning, afternoon, evening. Anything from that, that came out? DR MATULONIS: Not really. DR LOVE: Not really? DR MATULONIS: No. DR LOVE: Not a food-related type thing? DR MATULONIS: No. No. And we now know that patients can eat with the PARP inhibitor. That’s okay. |